Home » Stocks » Catalent

Catalent, Inc. (CTLT)

Stock Price: $88.87 USD 0.69 (0.78%)
Updated Aug 5, 2020 12:20 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 14.57B
Revenue (ttm) 2.87B
Net Income (ttm) 137.60M
Shares Out 163.81M
EPS (ttm) 0.69
PE Ratio 128.80
Forward PE 40.65
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 5, 2020
Last Price $88.87
Previous Close $88.18
Change ($) 0.69
Change (%) 0.78%
Day's Open 88.59
Day's Range 87.55 - 89.14
Day's Volume 152,740
52-Week Range 31.04 - 91.18

More Stats

Market Cap 14.57B
Enterprise Value 17.16B
Earnings Date (est) Aug 31, 2020
Ex-Dividend Date n/a
Shares Outstanding 163.81M
Float 154.05M
EPS (basic) 0.72
EPS (diluted) 0.69
FCF / Share -0.25
Dividend n/a
Dividend Yield n/a
Earnings Yield 0.78%
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.74M
Short Ratio 1.83
Short % of Float 2.20%
Beta 1.63
PE Ratio 128.80
Forward PE 40.65
P/FCF Ratio n/a
PS Ratio 5.07
PB Ratio 6.54
Revenue 2.87B
Operating Income 333.70M
Net Income 137.60M
Free Cash Flow -36.70M
Net Cash -2.59B
Net Cash / Share -15.80
Gross Margin 28.03%
Operating Margin 11.62%
Profit Margin 3.80%
FCF Margin -1.28%
ROA 3.95%
ROE 6.23%
ROIC 5.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (13)

Buy 9
Overweight 1
Hold 3
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(0.37% upside)
Current: $88.87
Target: 89.20
*Average 12-month price target from 10 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth2.22%18.7%12.3%0.94%0.17%1.52%6.22%10.64%-
Gross Profit805753655588615599569559502
Operating Income274269234218260241204198186
Net Income13783.6011011221216.20-49.60-24.40-54.00
Shares Outstanding146133125125124117117--
Earnings Per Share0.900.630.870.891.750.21-0.66-0.32-0.72
EPS Growth42.86%-27.59%-2.25%-49.14%733.33%----
Operating Cash Flow24837530015517217813887.9099.70
Capital Expenditures-218-175-139-138-141-122-120-102-83.30
Free Cash Flow30.1020016017.6030.8056.8018.10-14.1016.40
Cash & Equivalents34541028813215174.401061390.00
Total Debt2,9592,7212,0801,8611,8812,7112,6922,684-
Net Cash / Debt-2,614-2,311-1,791-1,729-1,730-2,636-2,585-2,5450.00
Book Value1,6821,087724636634-371-411-351-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Catalent, Inc.
Country United States
Employees 12,300
CEO John R. Chiminski

Stock Information

Ticker Symbol CTLT
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NYSE: CTLT
IPO Date July 31, 2014


Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics and Specialty Drug Delivery segment engages in the drug substance development and manufacturing; drug product clinical and commercial manufacturing; and integrated clinical and commercial supply solutions for protein and gene therapy biologics and specialty small molecules through injection, inhalation, and ophthalmic routes. The Oral Drug Delivery segment formulates, develops, and manufactures technologies and related integrated solutions for a range of oral dose forms, including its proprietary fast-dissolve Zydis tablets and conventional tablets, capsules, and sachet products. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain clinical supply services. The company serves pharmaceutical, biotechnology, consumer health, animal health, medical devices, and cosmetics industries. It has an agreement with Cycle Pharmaceuticals Ltd. to develop formulations targeting rare disease patients; a collaboration with the Janssen Pharmaceutical Companies, as well as Ennaid Therapeutics; a partnership with Arcturus Therapeutics Holdings Inc. to support the manufacture of LUNAR-COV19; and has collaboration with Moderna, Inc. for manufacturing mRNA-based COVID-19 vaccine candidate. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.